1
|
Current Limitations and Recent Advances in the Management of Asthma. Dis Mon 2022:101483. [DOI: 10.1016/j.disamonth.2022.101483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
2
|
|
3
|
Abstract
The most appropiate management for bronchial asthma is the control
of airway inflammation. Corticosteroids are the most effective
anti-inflammatory drugs available, but they have a number of side
effects; most of these are dose-dependent. In children, asthma
control should be accomplished with low steroid doses possibly given
by inhalation. In a double-bind placebo-controlled crossover study a
group of children with mild to moderate asthma received NED 16
mg/day or BDP 400 μg/day. Values for FEV1, PEF, symptoms use
ofbronchodilators overlapped, whereas bronchial hyper-responsiveness
assessed by histamine bronchoprovocation challenge was better with
BDP than NED. In another case, one boy with high bronchial
hyper-reactivity assessed by provocation test with hypertonic
solution, experienced a significant improvement only after 2 weeks
of therapy with Deflazacort (2 mg/Kg/day) followed by 4 months on
combined treatment with NED (16 mg/day) and BDP (300 μ/day). Authors
conclude that NED could have a steroidsparing effect over long-term use.
Collapse
|
4
|
Domingo C, Moreno A, Mirapeix R. Rationale for the use of immunomodulatory therapies in the Global Initiative for Asthma (GINA) step V asthma other than oral glucocorticosteroids. Intern Med J 2012; 41:525-36. [PMID: 21762333 DOI: 10.1111/j.1445-5994.2011.02481.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Asthma is a major problem worldwide, which is estimated to affect 300 million individuals. The global prevalence ranges from 1% to 18% of the population. The incidence, morbidity and mortality of the condition have increased over the last 50 years despite the development of new anti-asthmatic drugs. Fewer than 1% of the asthmatic population are steroid-dependent, but these patients consume most of the resources and time at asthma units. The consensus documents published by professional societies all support a stepwise therapeutic approach for asthma. However, patients who require frequent or continuous oral corticosteroid administration have received little attention. Due to the severe side-effects of oral corticosteroids when administered over long periods or at high doses, many drugs have been assessed in the search for a possible corticosteroid-sparing agent. Recently, the update of the Global Initiative for Asthma (GINA) introduced a new drug--omalizumab--as an alternative to oral corticosteroids in patients included in step V. Other alternatives include immunosuppressive drugs, among which methotrexate has been found to offer the best benefit/risk ratio. This paper will review, comment and criticize the evidence of the effectiveness of immunomodulatory drugs, as an alternative to oral glucocorticosteroid treatment in GINA step V asthma patients. The experience of the authors combined with the information of the literature will lead to the conclusion that methotrexate and omalizumab are the only advisable drugs and will clarify when and how these drugs should be used.
Collapse
Affiliation(s)
- C Domingo
- Pulmonary Service, Corporació Parc Taulí, Sabadell, Barcelona, Spain.
| | | | | |
Collapse
|
5
|
Onoue S, Sato H, Ogawa K, Kojo Y, Aoki Y, Kawabata Y, Wada K, Mizumoto T, Yamada S. Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats. Eur J Pharm Biopharm 2011; 80:54-60. [PMID: 22008148 DOI: 10.1016/j.ejpb.2011.10.003] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2011] [Revised: 09/24/2011] [Accepted: 10/03/2011] [Indexed: 11/30/2022]
Abstract
The main purpose of the present study was to develop a novel respirable powder (RP) formulation of cyclosporine A (CsA) using a spray-dried O/W-emulsion (DE) system. DE formulation of CsA (DE/CsA) was prepared by spray-drying a mixture of erythritol and liquid O/W emulsion containing CsA, polyvinylpyrrolidone, and glyceryl monooleate as emulsifying agent. The DE/CsA powders were mixed with lactose carriers to obtain an RP formulation of DE/CsA (DE/CsA-RP), and its physicochemical, pharmacological, and pharmacokinetic properties were evaluated. Spray-dried DE/CsA exhibited significant improvement in dissolution behavior with ca. 4500-fold increase of dissolution rate, and then, nanoemulsified particles were reconstituted with a mean diameter of 317 nm. Laser diffraction analysis on the DE/CsA-RP suggested high dispersion of DE/CsA on the surface of the lactose carrier. Anti-inflammatory properties of the inhaled DE/CsA-RP were characterized in antigen-sensitized asthma/COPD-model rats, in which the DE/CsA-RP was more potent than the RP formulation of physical mixture containing CsA and erythritol in inhibiting inflammatory responses, possibly due to the improved dissolution behavior. Pharmacokinetic studies demonstrated that systemic exposure of CsA after intratracheal administration of the DE/CsA-RP at a pharmacologically effective dose (100 μg-CsA/rat) was 50-fold less than that of the oral CsA dosage form at a toxic dose (10 mg/kg). From these findings, use of inhalable DE formulation of CsA might be a promising approach for the treatment of airway inflammatory diseases with improved pharmacodynamics and lower systemic exposure.
Collapse
Affiliation(s)
- Satomi Onoue
- Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, University of Shizuoka, Shizuoka, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
A case of severe bronchial asthma controlled with tacrolimus. J Allergy (Cairo) 2011; 2011:479129. [PMID: 21603171 PMCID: PMC3095904 DOI: 10.1155/2011/479129] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2010] [Accepted: 02/07/2011] [Indexed: 11/17/2022] Open
Abstract
Background. The control of severe bronchial asthma, such as corticosteroid-resistant asthma, is difficult. It is also possible that immunosuppressive agents would be effective for bronchial asthma.
Case Summary. A 55-year-old Japanese female presented with severe bronchial asthma controlled with tacrolimus. She had been diagnosed with bronchial asthma during childhood. Her asthma worsened, and a chest radiograph showed atelectasis of the left lung. Bronchoscopy revealed the left main bronchus to be obstructed with viscous sputum consisting of 82% neutrophils and no eosinophils. The atelectasis did not improve with corticosteroid treatment, but was ameliorated by administration of tacrolimus. Discussion. This patient had severe asthma due to neutrophilic inflammation of the airways. Tacrolimus is effective for treating severe asthma, for example, in corticosteroid-resistant cases.
Collapse
|
7
|
Morjaria JB, Polosa R. Recommendation for optimal management of severe refractory asthma. J Asthma Allergy 2010; 3:43-56. [PMID: 21437039 PMCID: PMC3047913 DOI: 10.2147/jaa.s6710] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2010] [Indexed: 11/23/2022] Open
Abstract
Patients whose asthma is not adequately controlled despite treatment with a combination of high dose inhaled corticosteroids and long-acting bronchodilators pose a major clinical challenge and an important health care problem. Patients with severe refractory disease often require regular oral corticosteroid use with an increased risk of steroid-related adverse events. Alternatively, immunomodulatory and biologic therapies may be considered, but they show wide variation in efficacy across studies thus limiting their generalizability. Managing asthma that is refractory to standard treatment requires a systematic approach to evaluate adherence, ensure a correct diagnosis, and identify coexisting disorders and trigger factors. In future, phenotyping of patients with severe refractory asthma will also become an important element of this systematic approach, because it could be of help in guiding and tailoring treatments. Here, we propose a pragmatic management approach in diagnosing and treating this challenging subset of asthmatic patients.
Collapse
|
8
|
Murphy P, Hillman T, Rajakulasingam K. Therapeutic targets for persistent airway inflammation in refractory asthma. Biomed Pharmacother 2009; 64:140-5. [PMID: 20074901 DOI: 10.1016/j.biopha.2009.10.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2009] [Accepted: 10/07/2009] [Indexed: 01/24/2023] Open
Abstract
The management of refractory asthma remains a compelling clinical problem that contributes significantly to the morbidity of patients as well as posing a financial burden to the health system. Treatment failure in this group of patients is associated with continued airway inflammation and dampening of the inflammatory cascade is the focus of much research in this area. Continued airway inflammation has been associated with higher patient morbidity and is being increasingly measured using markers of systemic and local inflammation in order to target therapy more effectively. This review focuses on the published evidence for both established and novel treatments in refractory asthma that act to control this pathological inflammatory process. No clear treatment yet exists to control this process and further research into inhibiting newly elucidated inflammatory pathways or new drugs more effectively or accurate targeting existing pathways are discussed along with the clinical evidence and the relative merits of each treatment.
Collapse
Affiliation(s)
- Patrick Murphy
- Department of Respiratory Medicine/Allergy, Homerton University Hospital NHS Foundation Trust, London, United Kingdom
| | | | | |
Collapse
|
9
|
Onoue S, Sato H, Kawabata Y, Mizumoto T, Hashimoto N, Yamada S. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release 2009; 138:16-23. [PMID: 19376169 DOI: 10.1016/j.jconrel.2009.04.014] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2009] [Revised: 04/08/2009] [Accepted: 04/12/2009] [Indexed: 02/07/2023]
Abstract
Cyclosporine A (CsA) has been clinically used as immunosuppressant, and new application for airway inflammation was also proposed. However, the clinical use of CsA was limited due to severe adverse effects after systemic exposure and the poor solubility. In the present investigation, novel respirable powder (RP) of CsA was developed for pulmonary administration with use of solid dispersion of wet-milled CsA (WM/CsA), and the physicochemical and pharmacological properties of the WM/CsA and its RP formulation were characterized. CsA in the solid dispersion was found to be amorphous by X-ray powder diffraction and differential scanning calorimetry. It exhibited the improved dissolution behavior as compared to active pharmaceutical ingredients. Laser diffraction and cascade impactor analysis of newly developed WM/CsA-RP, consisting of jet-milled WM/CsA and lactose carriers, suggested high dispersion and deposition in the respiratory organs with the emitted dose and the fine particle fraction of 96 and 54%, respectively. Intratracheal administration of WM/CsA-RP (100 microg CsA) in experimental inflammatory rats led to 71 and 85% reduction of granulocyte recruitment in bronchoalveolar lavage fluids and lung tissues, respectively, with showing ca 10(2)-fold reduced AUC and C(max) values of plasma CsA as compared to the oral dosage form of CsA at toxic concentration (10 mg/kg). Upon these findings, WM/CsA-RP would be efficacious dosage form for clinical treatment of airway inflammations with minimal systemic side effects.
Collapse
Affiliation(s)
- Satomi Onoue
- Department of Pharmacokinetics and Pharmacodynamics and Global Center of Excellence (COE) Program, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
| | | | | | | | | | | |
Collapse
|
10
|
Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med 2009; 102:1499-510. [PMID: 19012848 DOI: 10.1016/j.rmed.2008.09.006] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/30/2008] [Indexed: 11/30/2022]
Abstract
Despite undoubted efficacy of the combination of inhaled corticosteroids and beta(2)-agonists for most asthmatic patients with moderate-to-severe disease, there remains approximately 10% of the asthmatic population with serious unremitting symptoms, resulting in considerable impact on quality of life, disproportionate use of health care resources, and adverse effects from regular systemic steroid use. In an ideal world, optimal treatment of severe refractory asthma should achieve the best possible asthma control and quality of life with the least dose of systemic corticosteroids. The choice and formulation of therapeutic agent are dictated by the severity of disease and may include immunological modifiers and biologic therapies. Unfortunately, current asthma guidelines offer little contribution to the management of the challenging patient with severe refractory asthma and none of them have addressed therapeutic alternatives to oral corticosteroids. This article reviews the current evidence for immunomodulating and biologic approaches in severe refractory asthma.
Collapse
Affiliation(s)
- Riccardo Polosa
- Ospedale Santa Marta, U.O.C di Medicina Interna e Medicina d'Urgenza, Via Gesualdo Clementi 36, 95124 Catania, Italy.
| | | |
Collapse
|
11
|
Affiliation(s)
- Alexander S Niven
- Pulmonary/Critical Care Medicine Service, William Beaumont Army Medical Center, El Paso, TX 79920, USA.
| | | |
Collapse
|
12
|
Ellingsen I, Florvaag E, Andreassen AH, Iversen BM, Irgens A, Matre R. Plasmapheresis in the treatment of steroid-dependent bronchial asthma. Allergy 2001; 56:1202-5. [PMID: 11736751 DOI: 10.1034/j.1398-9995.2001.00141.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND Can plasmapheresis improve disease severity and lung function and reduce steroid doses in severe asthma patients dependent on oral corticosteroids? METHODS A pilot study with four asthma patients was undertaken using PEF (peak expiratory flow) symptom score, number of puffs of beta2-agonist, and dose of systemic steroids as disease variables. After at least an 8-week run-in, the patients were randomized to a crossover treatment regimen consisting of either 10 days of plasmapheresis or placebo treatment. Each treatment was succeeded by an 8-26-week follow-up period. RESULTS No patients achieved a significant effect of plasmapheresis treatment according to the established criteria, nor did anyone experience deterioration. CONCLUSIONS Removing humoral factors extensively over a 10-day period did not significantly influence the clinical condition of the four steroid-dependent asthma patients studied. Circulating humoral factors seem to be of little importance for the maintenance of the established chronic allergic inflammation in these patients. Plasmapheresis does not seem to be a treatment option for this patient category.
Collapse
Affiliation(s)
- I Ellingsen
- Department of Thoracic Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
| | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001; 2000:CD002993. [PMID: 11406057 PMCID: PMC8407285 DOI: 10.1002/14651858.cd002993] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. Physicians treating such patients continue to search for alternative therapies that reduce the need for chronic dosing with oral steroids. Cyclosporin is an immunosuppressive agent and has benefits in the treatment of a number of inflammatory disorders. It has therefore been identified as an potentially useful agent in the treatment of chronic severe asthma both in terms of possible efficacy and as a steroid sparing agent. OBJECTIVES The objective of this review was to assess the effects of adding cyclosporin to oral steroids in the treatment of chronic steroid dependent asthmatics. SEARCH STRATEGY The Cochrane Airways Group trials register and reference lists of identified articles were searched. SELECTION CRITERIA Randomised trials looking at the addition of cyclosporin compared to placebo in adult steroid dependent asthmatics. DATA COLLECTION AND ANALYSIS Trial quality was assessed and data extraction was carried out by two reviewers independently. Study authors were contacted for missing information. MAIN RESULTS Three trials fulfilled the criteria for inclusion in the review and a total of 106 patients were recruited into these studies. Data from 98 patients could be analysed. There was a small but significant treatment effect for cyclosporin in terms of steroid dose reduction (SMD -0.5, 95% CI -1.0, -0.04). No meta-analyses could be performed for measures of lung function although one study showed small, but significant improvements in lung spirometry. REVIEWER'S CONCLUSIONS The changes with cyclosporin are small and of questionable clinical significance. Given the side effects of cyclosporin, the evidence available does not recommend routine use of this drug in the treatment of oral corticosteroid dependent asthma.
Collapse
Affiliation(s)
- D J Evans
- Respiratory Centre, St Mary's Hospital, Milton Road, Portsmouth, UK, PO3 6AD.
| | | | | |
Collapse
|
15
|
Rohatagi S, Calic F, Harding N, Ozoux M, Bouriot J, Kirkesseli S, DeLeij L, Jensen BK. Pharmacokinetics, Pharmacodynamics, and Safety of Inhaled Cyclosporin A (ADI628) after Single and Repeated Administration in Healthy Male and Female Subjects and Asthmatic Patients. J Clin Pharmacol 2000. [DOI: 10.1177/009127000004001106] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- S. Rohatagi
- Department of Drug Metabolism and Pharmacokinetics, Aventis Pharmaceutical (formerly Rhône Poulenc‐Rorer), Collegeville, Pennsylvania
| | - F. Calic
- Department of Clinical Pharmacology, Aventis Pharmaceutical (formerly Rhône Poulenc‐Rorer), Antony, France
| | - N. Harding
- Department of Clinical Pharmacology, Aventis Pharmaceutical (formerly Rhône Poulenc‐Rorer), Antony, France
| | - M‐L. Ozoux
- Department of Drug Metabolism and Pharmacokinetics, Aventis Pharmaceutical (formerly Rhône Poulenc‐Rorer), Antony, France
| | - J‐P. Bouriot
- Department of Drug Metabolism and Pharmacokinetics, Aventis Pharmaceutical (formerly Rhône Poulenc‐Rorer), Antony, France
| | - S. Kirkesseli
- Department of Clinical Pharmacology, Aventis Pharmaceutical (formerly Rhône Poulenc‐Rorer), Collegeville, Pennsylvania
| | - L. DeLeij
- Department of Clinical Immunology, University Hospital Groningen, the Netherlands
| | - B. K. Jensen
- Department of Drug Metabolism and Pharmacokinetics, Aventis Pharmaceutical (formerly Rhône Poulenc‐Rorer), Collegeville, Pennsylvania
| |
Collapse
|
16
|
Abstract
Until the recent introduction of long acting beta 2-agonists and the leukotriene antagonists, the drug treatment of asthma had remained largely unchanged for a quarter century. Recent studies have demonstrated the efficacy of the long acting beta 2-agonists in the management of asthma in children and highlighted their value as an adjunct to inhaled corticosteroids. The leukotriene antagonists are an important new class of drug therapy which target a specific area of asthma pathogenesis. Whilst they have been shown to be effective for asthma, their exact role in the clinical situation remains to be established. Recent guidelines have emphasised the important role of inflammation in persistent asthma and recommended the early institution of anti-inflammatory treatment. Many patients remain uncontrolled despite high doses of anti-inflammatory agents including oral corticosteroids. Recent experience with other immunomodulatory agents such as cyclosporin, methotrexate and intravenous immunoglobulin has highlighed their potential as steroid sparing agents. With improved understanding of asthma pathogenesis the potential for specific targeted therapies has become evident. Monoclonal antibodies to IgE and certain cytokines are being investigated as possible treatments for asthma. Similarly, preliminary studies of selective phosphodiesterase inhibitors in asthmatic individuals have been encouraging. Other potential therapies include platelet-activating factor receptor antagonists, tryptase inhibitors and prostaglandin E analogs. The continued development of such targeted treatments should ensure a greater diversity of therapeutic options for the management of asthma in the new millennium.
Collapse
Affiliation(s)
- J Legg
- Institute of Child Health, Southampton University, U.K
| | | |
Collapse
|
17
|
Klyashchitsky BA, Owen AJ. Nebulizer-compatible liquid formulations for aerosol pulmonary delivery of hydrophobic drugs: glucocorticoids and cyclosporine. J Drug Target 2000; 7:79-99. [PMID: 10617295 DOI: 10.3109/10611869909085494] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
This review discusses pulmonary delivery of glucocorticoids and cyclosporine in pharmaceutically acceptable organic solvents and liposomes, as well as in micellar solutions and microemulsions, by means of liquid aerosols generated by nebulizers. The review points out the importance of a variety of parameters for successful treatment of immunologically mediated lung diseases by inhalation of drug containing aerosols with particular references to physico-chemical properties of formulations, aerosol parameters, pharmacokinetics, and lung deposition in experimental animals and humans. The prospects for the use of these types of formulations for clinical treatment of asthma, lung transplant rejection processes and other lung diseases are summarized.
Collapse
|
18
|
|
19
|
Abstract
The past decade has seen significant advances in the available treatments for asthma. These include longer-acting bronchodilating agents, high topical potency inhaled corticosteroids, and agents that interfere with leukotriene production or action. Table 3 summarizes the clinical effects of the newer therapeutic agents reviewed. Experimental therapies for the steroid-dependent patient have also been discussed. Although clinical trials to date have established many of these as effective in asthma, the results of ongoing, large, multicenter studies investigating the relative merits of these therapies, alone and in combination, will further clarify how to maximize the utility of these agents in the treatment of asthma.
Collapse
Affiliation(s)
- A Deykin
- Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | | |
Collapse
|
20
|
Mitchell RW, Cozzi P, Ndukwu IM, Spaethe S, Leff AR, Padrid PA. Differential effects of cyclosporine A after acute antigen challenge in sensitized cats in vivo and ex vivo. Br J Pharmacol 1998; 123:1198-204. [PMID: 9559905 PMCID: PMC1565269 DOI: 10.1038/sj.bjp.0701716] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
1. We determined the effect of cyclosporine A (CsA) treatment on mast cell degranulation and lung resistance (R(L)) in vivo, and tracheal smooth muscle (TSM) contraction ex vivo after antigen challenge in sensitized cats. We also determined the direct effects of addition of CsA to the tissue bath on antigen-induced responses of TSM in vitro. 2. Cats (n=10) were sensitized by i.m. injection of Ascaris suum antigen (AA); 5 cats (CsA+) received CsA twice daily for 2 weeks before acute antigen challenge in doses sufficient to suppress interleukin-2 secretion from feline peripheral blood mononuclear cells ex vivo. 3. Lung resistance increased comparably within 10 min of exposure to AA (P<0.03). Histamine content in bronchoalveolar lavage fluid from both groups increased comparably within 30 min of antigen challenge, from undetectable levels to 542+/-74 pg ml(-1) post AA for CsA+ and from 74+/-19 pg ml(-1) at baseline, to 970+/-180 pg ml(-1) post AA CsA- (P<0.05; P=NS vs CsA+). 4. In excised TSM, active tension elicited by exposure to AA in vitro was 107+/-38% KCl in the CsA+ group vs 144+/-56% KCl in the CsA- group (P=NS). However, contraction of TSM (n=4) harvested from both groups was abolished or greatly diminished after AA challenge when tissues were pre-incubated with 1 microM CsA in vitro (8+/-8% KCl, P<0.05 vs CsA+ and CsA-). This was associated with inhibited release of 5-hydroxytryptamine into the organ bath fluid of tissues treated with CsA in vitro only. 5. We demonstrated that CsA treatment in vivo does not inhibit the early phase asthmatic response or mast cell degranulation following antigen challenge in sensitized cats. Additionally, the effects of CsA on mast cell function ex vivo do not reflect lack of effects of CsA on mast cell function in vivo in this animal model of atopic asthma.
Collapse
Affiliation(s)
- R W Mitchell
- Department of Medicine, The University of Chicago, IL 60637, USA
| | | | | | | | | | | |
Collapse
|
21
|
Redington AE, Hardinge FM, Madden J, Holgate ST, Howarth PH. Cyclosporin A treatment and airways inflammation in corticosteroid-dependent asthma. Allergy 1998; 53:94-8. [PMID: 9491236 DOI: 10.1111/j.1398-9995.1998.tb03780.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Cyclosporin A is a potent immunosuppressive agent which inhibits activation of T cells and other inflammatory cells. It has been shown to be of clinical benefit in patients with corticosteroid-dependent asthma, but there are no data on its in vivo effects on airways inflammation. In this report, we describe the case of a 47-year-old man with chronic severe corticosteroid-dependent asthma who made a dramatic clinical response to therapy with cyclosporin A. Fibreoptic bronchoscopy with bronchoalveolar lavage and endobronchial biopsy were performed before and after a 12-month period of treatment with cyclosporin A and demonstrated a concomitant reduction in airway inflammatory indices.
Collapse
|
22
|
Gilbert BE, Knight C, Alvarez FG, Waldrep C, Rodarte JR, Knight V, Eschenbacher WL. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med 1997; 156:1789-93. [PMID: 9412556 DOI: 10.1164/ajrccm.156.6.9702101] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Cyclosporine A (CsA) in liposomes of dilauroylphosphatidylcholine (DLPC), containing 118 micrograms of CsA/L of aerosol with a particle size of 1.6 to 1.7 micron diameter, was inhaled by 10 nonsmoking, normal volunteers each for 45 min. Aerosol was administered through an Aerotech II nebulizer (CIS-US, Inc., Bedford, MA) mouthpiece. Eight of the 10 volunteers had tracheal irritation and intermittent coughing following exposure. FEV1 and FVC values were mildly reduced, but returned to normal in 1 h. Blood chemical and hematologic values were unchanged at any time point after as opposed to before inhalation. Nine of the 10 volunteers later inhaled DLPC only, administered through the nebulizer mouthpiece. There was no change in FEV1 or FVC values, and there was no coughing or tracheal irritation. Subsequently, five of the volunteers who had previously had respiratory reactions inhaled CsA-DLPC liposome aerosol for 45-min, but through a mouth-only face mask. There was no tracheal irritation, coughing, or changes in spirometric measures. Blood concentrations of CsA at 15 min after the 45-min inhalation with a face mask averaged 83 +/- 42 ng/ml (mean +/- SD). At 24 h after treatment, CsA was undetectable in blood of the initial 10 volunteers. These studies indicate that CsA-DLPC liposome aerosol can be safely explored as a treatment for patients with moderately severe asthma.
Collapse
Affiliation(s)
- B E Gilbert
- Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Spahn JD, Leung DY, Szefler SJ. New insights into the pathogenesis and management of steroid-resistant asthma. J Asthma 1997; 34:177-94. [PMID: 9168845 DOI: 10.3109/02770909709068188] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A population of difficult-to-control asthmatics exists who, despite high-dose daily GC therapy, continue to display evidence for active disease. This group has been termed steroid resistant since they fail to adequately respond to aggressive courses of high-dose oral and inhaled GC therapy. Persistent immune activation and airway inflammation which to varying degrees is resistant to GC therapy appears to define the immunological abnormality underlying SR asthma. Recent studies utilizing molecular biological techniques have identified both ligand- and DNA-binding defects that could possibly account for steroid resistance at a molecular level. The evaluation of the SR asthmatic must be comprehensive in its scope as several confounding factors can contribute to this symptom complex. Among others, these include poor compliance, improper medication technique, inadequate anti-inflammatory therapy, unrecognized contributing diseases, incorrect diagnoses, environmental factors, and psychosocial disturbances. The management of the SR asthmatic is challenging, and every attempt should be made to maximize conventional therapy in these patients prior to embarking on alternative therapies as all of the alternative anti-inflammatory/immunomodulatory modalities are associated with significant toxicity or cost. Second-generation inhaled GC therapy, methotrexate, cyclosporine, IVIG, and leukotriene antagonists are potential alternative therapies, and although they remain viable options, they have been used in small numbers, and for short periods of time, and fail to result in long-term remissions. Although much insight into the pathogenesis of SR asthma has been gained, several issues remain unresolved. Ongoing airway inflammation is thought to contribute to steroid resistance, but at present, we have no standard method of determining the degree of inflammation. The incorporation of bronchoscopy with transbronchial biopsy has the potential to provide the greatest amount of information regarding the presence or absence of ongoing airway inflammation, but the invasive nature of the procedure precludes its use in pediatric patients and the most severe adult asthmatics. Large multicenter, placebo-controlled studies evaluating the available alternative therapies that incorporate markers of airway inflammation are needed, as are studies that evaluate these therapies over longer periods of time. It is hoped that by better understanding the mechanisms involved and the natural history of the SR asthmatic, specific treatment modalities will be developed for this challenging group of severe asthmatics.
Collapse
Affiliation(s)
- J D Spahn
- Division of Clinical Pharmacology, Ira J. and Jacqueline Neimark Laboratory of Clinical Pharmacology in Pediatrics, Denver, Colorado, USA
| | | | | |
Collapse
|
24
|
TREATMENT OF STEROID-RESISTANT ASTHMA. Radiol Clin North Am 1996. [DOI: 10.1016/s0033-8389(22)00244-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
25
|
|
26
|
Nimmagadda SR, Spahn JD, Leung DY, Szefler SJ. Steroid-resistant asthma: evaluation and management. Ann Allergy Asthma Immunol 1996; 77:345-55; quiz 355-6. [PMID: 8933772 DOI: 10.1016/s1081-1206(10)63332-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
LEARNING OBJECTIVES Reading this article will reinforce the reader's knowledge of the definition, pathophysiology, differential diagnosis, and treatment of the steroid-resistant asthmatic patient. DATA SOURCES Prospective and retrospective data from the authors' experience were evaluated. In addition, a Medline database was searched from 1981, using the key words "asthma," "glucocorticoids," and "glucocorticoid resistance" with the restrictions of English language and human subjects. Relevant articles referenced in retrieved sources and current texts on severe asthma were also utilized. STUDY SELECTION Data source abstracts, pertinent articles, and book chapters meeting the objectives were critically reviewed. RESULTS Although rare, individuals with steroid-resistant asthma are often the most difficult-to-manage asthmatic patients in that they have severe disease yet fail to respond to glucocorticoids. To make the diagnosis of steroid-resistant asthma, the patient must fail to respond to a 7 to 14-day course of daily prednisone as measured by less than a 15% improvement in morning prebronchodilator FEV1 following the glucocorticoid course. Ongoing inflammation is thought to play a major role in the pathogenesis of steroid-resistant asthma, and recent studies have demonstrated diminished glucocorticoid receptor to glucocorticoid, or diminished glucocorticoid receptor to DNA binding as possible mechanisms for diminished glucocorticoid responsiveness. Alternative asthma therapies such as methotrexate, cyclosporine, and intravenous gammaglobulin are often used in this group of asthmatic patients. CONCLUSIONS The patient with steroid-resistant asthma presents several challenges. These individuals often display many of the sequelae of long-term systemic glucocorticoid use while achieving little therapeutic benefit. Prior to making the diagnosis of steroid-resistant asthma, diseases that can contribute to poor control of asthma must be ruled out, and noncompliance issues addressed. Alternative asthma therapies are often used; however, they also carry the potential for adverse effects, and have not been thoroughly studied in this population of asthmatic patients.
Collapse
Affiliation(s)
- S R Nimmagadda
- Ira J. and Jacqueline Neimark Laboratory of Clinical Pharmacology in Pediatrics, University of Colorado Health Sciences Center, Denver, USA
| | | | | | | |
Collapse
|
27
|
Busse WW, McGill K, Jarjour NN. Current management of asthma patients with corticosteroid resistance. Am J Respir Crit Care Med 1996; 154:S70-2; discussion S72-3. [PMID: 8756793 DOI: 10.1164/ajrccm/154.2_pt_2.s70] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Affiliation(s)
- W W Busse
- University of Wisconsin, Madison, USA
| | | | | |
Collapse
|
28
|
Abstract
Immunomodulatory agents represent a unique group of therapies that are not biologics and have relatively specific, noncytotoxic effects on the immune system. Cyclosporine has been the most widely tested of the immunomodulatory agents and shown efficacy in a variety of autoimmune diseases as well as monotherapy in established rheumatoid arthritis. FK-506 and rapamycin, agents similar to cyclosporine, are being tested in human transplantation, with only arthritis studies having been done in animals. Tilomisole, imuthiol, and mycophenolate mofetil have been studied in limited rheumatoid arthritis trials with positive effects. Although more specific and with manageable short-term side effects, this group of therapies requires more studies to establish their efficacy and long-term safety.
Collapse
Affiliation(s)
- D E Yocum
- Arizona Health Sciences Center, University of Arizona, Tucson, USA
| |
Collapse
|
29
|
Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, Vigouret JM. In vivo pharmacological effects of ciclosporin and some analogues. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 1996; 35:115-246. [PMID: 8920206 DOI: 10.1016/s1054-3589(08)60276-8] [Citation(s) in RCA: 99] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- J F Borel
- Sandoz Pharma AG, Preclinical Research Division, Basel Switzerland
| | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- R B Moss
- Department of Pediatrics, Stanford University Medical Center, CA 94305-5119
| |
Collapse
|
31
|
Abstract
This review presents the progress and some aspects achieved during recent years with cyclosporin sources, chemistry, biological activities, side effects, biosynthesis and metabolism. Although incomplete the results indicate future research trends and some white spots to be studied in the near future to afford unique insights into cell biology and to improve the search for similar and even more specific agents based on rational drug design.
Collapse
|
32
|
Affiliation(s)
- T Fukuda
- Department of Internal Medicine and Clinical Immunology, Dokkyo University School of Medicine, Tochigiken, Japan
| |
Collapse
|
33
|
Dukes MN, Holgate ST, Pauwels RA. Report of an international workshop on risk and safety of asthma therapy. Clin Exp Allergy 1994; 24:160-5. [PMID: 8187032 DOI: 10.1111/j.1365-2222.1994.tb00214.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
34
|
Sorkness CA, Bush RK. ALTERNATIVES TO CORTICOSTEROIDS IN THE TREATMENT OF ASTHMA. Immunol Allergy Clin North Am 1993. [DOI: 10.1016/s0889-8561(22)00667-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
|
36
|
Affiliation(s)
- P J Barnes
- Department of Thoracic Medicine, National Heart and Lung Institute, London, UK
| | | |
Collapse
|
37
|
Abstract
Evidence is accumulating that inflammation of the airways is directly responsible for the increased bronchial hyperresponsiveness (BHR) and lung function obstruction in asthma. Bronchoprovocation with non-specific, direct bronchoconstrictors (methacholine and/or histamine) can be used as an indirect measurement of inflammation. Thus bronchoprovocation is a useful method for evaluating the long-term benefits of various therapies in asthma. The focus of asthma therapy research is now on the development of anti-inflammatory agents. Inhaled corticosteroids are currently the most potent anti-inflammatory agents in the treatment of asthma and so are generally the most effective in reducing BHR with long-term use. Non-corticosteroid anti-inflammatory agents that are currently available are reviewed. Recent studies have suggested that regular use of inhaled bronchodilators may actually be detrimental in asthma. At this time the data is still inconclusive but certainly warrants the attention of practitioners and requires further research, particularly in relation to the long-acting beta 2-agonists, formoterol and salmeterol.
Collapse
Affiliation(s)
- H W Kelly
- College of Pharmacy, University of New Mexico, Albuquerque 87131-1066
| |
Collapse
|
38
|
Abstract
The treatment of asthma is undergoing significant change with an emphasis on anti-inflammatory therapy. While glucocorticoids are the most potent anti-inflammatory agent, certain patients fail to respond. These patients may be candidates for alternative anti-inflammatory therapy, such as troleandomycin, methotrexate, gold, hydroxychloroquine, or dapsone. In addition, the application of immunomodulator therapy, such as intravenous gamma globulin or cyclosporine, may be useful.
Collapse
Affiliation(s)
- S J Szefler
- Department of Pediatrics, University of Colorado Health Sciences Center, Denver
| |
Collapse
|